enVVeno Medical is a late stage clinical med-tech company focused on the development of bioprosthetic (tissue-based) solutions. Co. is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. Co.'s primary product is the VenoValve®, which is a porcine based replacement venous valve to be surgically implanted in the deep venous system of the leg to treat severe CVI. Co. is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve for the treatment of CVI of the deep veins of the leg. The NVNO stock yearly return is shown above.
The yearly return on the NVNO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NVNO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|